Skip to main content
60 DEGREES PHARMACEUTICALS, INC. logo

60 DEGREES PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · SXTP ISIN · US83006G1040 US Manufacturing
Open in API
Filings indexed 192 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US SXTP

About 60 DEGREES PHARMACEUTICALS, INC.

https://60degreespharma.com/

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines for infectious diseases. The company's primary efforts are directed towards tropical diseases with significant unmet medical needs. Its portfolio includes a commercially available product for malaria prevention and a development program for a dengue fever treatment. The company's clinical pipeline also extends to other infectious diseases, such as babesiosis. Through collaborations with research organizations, 60 Degrees Pharmaceuticals aims to discover, develop, and distribute innovative therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings
2026-05-18 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
Regulatory Filings
2026-03-20 English
8-K Filing
Regulatory Filings
2026-02-12 English
CURRENT REPORT
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The key content is the notice of delisting from Nasdaq due to failure to maintain the minimum bid price and the immediate delisting due to a recent reverse stock split. The document includes details about the delisting notice, the company's appeal, and the regulatory context. There are no financial statements or detailed financial data, nor is this an annual or quarterly report. It is a formal announcement of a delisting event, which matches the definition of a Delisting Announcement (DLST). The document length is about 5,415 characters, which is sufficient for a full announcement rather than a brief notice or a report publication announcement. Therefore, the correct classification is DLST with high confidence.
2026-01-23 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details a reverse stock split approved by the board and stockholders, including the filing of a Certificate of Amendment to the Certificate of Incorporation. It also references a press release attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a capital structure change (reverse stock split), which fits the category of Capital/Financing Update (CAP). The length of the document (5967 characters) and the detailed description of the reverse stock split support this classification with high confidence.
2026-01-21 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.